Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
August 23, 2014, 08:00:49 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 635781
  • Total Topics: 48235
  • Online Today: 314
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 6
Guests: 158
Total: 164

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Short-Circuiting HIV Replication  (Read 1448 times)

0 Members and 1 Guest are viewing this topic.

Offline Tadeys

  • Member
  • Posts: 159
Short-Circuiting HIV Replication
« on: January 21, 2013, 03:22:50 PM »
In the Jan. 21 early edition of the Proceedings of the National Academy of Sciences, investigators reported that they have discovered an exploitable mechanism to rid the body of HIV.

Current antiretroviral drugs effectively suppress the virus, explains James Stivers, Ph.D., a professor of pharmacology and molecular sciences at the Johns Hopkins University School of Medicine's Institute for Basic Biomedical Sciences, and colleagues at University of California, San Diego and the University of Utah School of Medicine, but they don't get at copies of the virus lurking in the DNA of in nondividing cells. "And," he says, "the minute you stop taking antiretrovirals, it starts replicating again."

HIV, like other viruses with RNA genomes, makes a DNA copy of itself in its target cells, integrating itself into the cell's DNA, then relying on certain cellular components to reproduce. But cellular DNA replication, an error-prone process, depends on multiple control mechanisms to rid replicating DNA of incorrect bases that become inserted in the process. For example, many DNA polymerases cannot discriminate between dUTP found in RNAs and dTTP, which is restricted to DNA, mistakenly putting a uracil in the nascent DNA chain where there should be a thymine.

To control dUTP levels, says Dr. Stivers, most human cell types have an enzyme that breaks down dUTP, uracil DNA glycosylase (dUTPase). As another fail-safe measure, the enzyme hUNG2 snips stray uracils out of newly copied DNA strands, leaving the resulting holes to be filled by a different repair enzyme. Certain resting cells targeted by the virus lack the first quality-control mechanism because, Stivers explains, "They're not replicating their DNA and dividing, so they couldn't care less if they have a lot of dUTP."

When a retrovirus like HIV invades a cell, it immediately makes DNA copies of its own RNA genome, then inserts them into the host cell genome. If there are many dUTPs floating around, they wind up in the new viral DNA, and, potentially, are removed by hUNG2. The question, Stivers said, left open by the conflicting results of previous studies, was what effect, if any, this process has on HIV and similar viruses.

The investigators found, in measuring dUTP levels and hUNG2 activity in human cells grown in vitro then exposed to HIV, that cells with high dUTP but little hUNG2 activity were highly susceptible to the virus, as were cells with low dUTP levels but high hUNG2. In cells with high UNG2 levels, the enzyme would snip out the few stray Us, but the resulting holes would be repaired, leaving the viral DNA as "good as new."

But in cells with both high dUTP and vigilant hUNG2, Dr. Stivers said, the repair process left the viral DNA so riddled with holes that it was beyond repair. "It's like dropping a nuclear bomb on the viral genome," he said.

Stivers noted that dUTP may turn out to be a "potentially interesting pharmacologic target against HIV-1." Further, a protein expressed by HIV degrades UNG in some immune cells, he explains. Unable to repair damaged DNA, these cells are then more prone to infection. If researchers designed a drug that blocks the interaction between the HIV protein and UNG, they might be able to protect the immune cells from infection, he said.

http://www.genengnews.com/gen-news-highlights/short-circuiting-hiv-replication/81247886/

Offline OneTampa

  • Member
  • Posts: 2,159
  • "Butterflies are free."
Re: Short-Circuiting HIV Replication
« Reply #1 on: January 24, 2013, 12:52:43 PM »
Is this similar to the announcement from the Stanford University School of Medicine?

http://med.stanford.edu/ism/2013/january/porteus.html
"He is my oldest child. The shy and retiring one over there with the Haitian headdress serving pescaíto frito."

Offline Dr.Strangelove

  • Member
  • Posts: 207
Re: Short-Circuiting HIV Replication
« Reply #2 on: January 25, 2013, 05:50:28 AM »
No, it's something completely different.

The Stanford people have found a clever way to further improve the Sangamo approach. In their current approach Sangamo draws blood from a patient, seperated the CD4 cells and infuses them with a designed zinc-finger-nuclease that can specifically bind to the gene of the CCR5 receptor. A small piece of that gene is cut out and therefore no functional receptor can be produced by that CD4 cell anymore. Then the immunized cells are infused back into the blood stream of the patient.
While the CCR5 receptor of CD4 cells is the main entry gate for HIV into the human body, it is not the only one. The Stanford researchers have added an additional step. Instead of just cutting out a piece of the CCR5 gene and thus deactivating it, they add three additional genes in that place. The proteins that are expressed by those genes further protect the cell from HIV.

Now, the PNAS paper of the John Hopkins researchers is a whole different thing. I'm rather skeptic about that one for several reasons. I would be surprised if this ever makes it into any form of HIV treatment or prevention.

Offline Mishma

  • Member
  • Posts: 190
    • Marquis de Vauban
Re: Short-Circuiting HIV Replication
« Reply #3 on: January 25, 2013, 03:00:24 PM »
I knew folks that were doing gene knockins while I was doing gene knockouts to study genes and their regulation. Usually we both added or deleted several (1-100) base pairs so as to render the homologous recombined "gene," non functional (aka knockout) or hyperfunctional (HIV steals one of our important immunoregulatory elements, transcription factor NFkb, in its reading frame.) aka knockins. I'm surprised that these "stacks" are even functional. More than just linear base pairs though, as DNA's 3 dimensional feature is also a compounding variable and adding or removing 3 genes and knocking one out (zinc finger) could very well change its structure. Throw in the epigenetics and......... We'll need replication and years to know more. Indeed this is promising. 
2016 CD4 25% UD (less than 20). 27+ years positive. Isentress, Truvada, Acyclovir, Clonazepam, Zolpidem, Bupropion, Lisinopril, Pravastatin, Quetiapine, Doxcycline, Testosterone, Suatriptan/Naproxen, Restasis, Dorzolamide, Latanoprost, Asprin, lortab, Levothyroxine, Fioricet, Restasis, Triamclinolone, Nitrostat.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.